In patient samples from the PUNCH CD2 trial, we demonstrated reduced fecal levels of primary BAs and restored secondary BAs in patients who responded to treatment with RBX2660 (i.e., no recurrence of CDI in 8 weeks post treatment). Here, CD2 is linked to clostridium difficile infection.